Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

CANF has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 4.9 %

Shares of NYSE:CANF opened at $1.49 on Tuesday. The company has a 50 day moving average of $1.54 and a 200 day moving average of $2.04. The stock has a market cap of $5.27 million, a P/E ratio of -0.83 and a beta of 1.33. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.